Who shouldnt use these peptides: Anyone with active cancer or a recent cancer history (GH and IGF-1 can stimulate growth of some malignancies) Severe uncontrolled diabetes, GH worsens insulin resistance Active proliferative diabetic retinopathy Pregnancy or breastfeeding Children or adolescents (growth plates still open) FDA 503A and what changed for sermorelin compounding This is the part of the conversation most clinic-marketing pages avoid, and it matters enough that you should know it before you start.In late 2023, the FDA reclassified sermorelins bulk substance status, removing it from the 503A compounding pathway that traditional compounding pharmacies operate under
However, the therapeutic effects, particularly appetite suppression, are strongest during the first 5 to 7 days
More Energy - helps keep you going through long sessions
Our experience shows that the most common source of inconsistent data in peptide research doesn't come from the peptide's quality (assuming you're sourcing from a reputable lab like ours) but from these seemingly small procedural inconsistencies
Our programs include ongoing support and access to specialists who can answer questions about timing, side effects, and long-term management